IRIDEXIRIX
About: IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Employees: 139
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.61% less ownership
Funds ownership: 20.01% [Q3] → 19.4% (-0.61%) [Q4]
4% less funds holding
Funds holding: 28 [Q3] → 27 (-1) [Q4]
7% less capital invested
Capital invested by funds: $5.83M [Q3] → $5.43M (-$394K) [Q4]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Research analyst outlook
We haven’t received any recent analyst ratings for IRIX.
Financial journalist opinion
Based on 5 articles about IRIX published over the past 30 days









